These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Transformation of the 5q- syndrome to acute lymphoblastic leukemia: a report of two cases and review of the literature. Agostino NM; Ahmed B; Popescu D; Gheith S Int J Clin Exp Pathol; 2011 Mar; 4(3):322-6. PubMed ID: 21487529 [TBL] [Abstract][Full Text] [Related]
24. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091 [TBL] [Abstract][Full Text] [Related]
25. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Morishita K; Parganas E; William CL; Whittaker MH; Drabkin H; Oval J; Taetle R; Valentine MB; Ihle JN Proc Natl Acad Sci U S A; 1992 May; 89(9):3937-41. PubMed ID: 1570317 [TBL] [Abstract][Full Text] [Related]
26. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Raynaud SD; Baens M; Grosgeorge J; Rodgers K; Reid CD; Dainton M; Dyer M; Fuzibet JG; Gratecos N; Taillan B; Ayraud N; Marynen P Blood; 1996 Jul; 88(2):682-9. PubMed ID: 8695816 [TBL] [Abstract][Full Text] [Related]
27. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients. Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125 [TBL] [Abstract][Full Text] [Related]
28. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Lugthart S; van Drunen E; van Norden Y; van Hoven A; Erpelinck CA; Valk PJ; Beverloo HB; Löwenberg B; Delwel R Blood; 2008 Apr; 111(8):4329-37. PubMed ID: 18272813 [TBL] [Abstract][Full Text] [Related]
29. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements. Sitailo S; Sood R; Barton K; Nucifora G Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037 [TBL] [Abstract][Full Text] [Related]
30. A novel variant of acute myelomonocytic leukemia carrying t(3;12)(q26;p13) with characteristics of 3q21q26 syndrome. Iwase S; Furukawa Y; Horiguchi-Yamada J; Nemoto T; Takahara S; Kawano T; Sekikawa T; Ito K; Yamazaki Y; Kikuchi J; Morishita K; Yamada H Int J Hematol; 1998 Jun; 67(4):361-8. PubMed ID: 9695409 [TBL] [Abstract][Full Text] [Related]
31. Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Suzukawa K; Parganas E; Gajjar A; Abe T; Takahashi S; Tani K; Asano S; Asou H; Kamada N; Yokota J Blood; 1994 Oct; 84(8):2681-8. PubMed ID: 7919381 [TBL] [Abstract][Full Text] [Related]
32. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Gröschel S; Sanders MA; Hoogenboezem R; de Wit E; Bouwman BAM; Erpelinck C; van der Velden VHJ; Havermans M; Avellino R; van Lom K; Rombouts EJ; van Duin M; Döhner K; Beverloo HB; Bradner JE; Döhner H; Löwenberg B; Valk PJM; Bindels EMJ; de Laat W; Delwel R Cell; 2014 Apr; 157(2):369-381. PubMed ID: 24703711 [TBL] [Abstract][Full Text] [Related]
33. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome. Jaju RJ; Jones M; Boultwood J; Kelly S; Mason DY; Wainscoat JS; Kearney L Genes Chromosomes Cancer; 2000 Nov; 29(3):276-80. PubMed ID: 10992302 [TBL] [Abstract][Full Text] [Related]
34. Acute panmyelosis with myelofibrosis with EVI1 amplification. Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625 [TBL] [Abstract][Full Text] [Related]
35. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738 [TBL] [Abstract][Full Text] [Related]
36. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms]. Tanaka A Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237 [TBL] [Abstract][Full Text] [Related]
37. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; van Putten WL; Valk PJ; van der Poel-van de Luytgaarde S; Hack R; Slater R; Smit EM; Beverloo HB; Verhoef G; Verdonck LF; Ossenkoppele GJ; Sonneveld P; de Greef GE; Löwenberg B; Delwel R Blood; 2003 Feb; 101(3):837-45. PubMed ID: 12393383 [TBL] [Abstract][Full Text] [Related]
38. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172 [TBL] [Abstract][Full Text] [Related]
39. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737. Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393 [TBL] [Abstract][Full Text] [Related]
40. MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Sood R; Talwar-Trikha A; Chakrabarti SR; Nucifora G Leukemia; 1999 Mar; 13(3):348-57. PubMed ID: 10086725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]